Prostate Cancer Diagnostics - Global Market Outlook (2020-2028)

Global Prostate Cancer Diagnostics Market is accounted for $3.20 billion in 2020 and is expected to reach $9.94 billion by 2028 growing at a CAGR of 15.2% during the forecast period. Increasing prevalence of prostate cancer, increasing awareness regarding early detection and availability of advanced methodologies present in the medical field are driving the market growth. However, high cost of diagnostics procedure, lack of skilled and certified professionals is hampering the growth of the market.

Prostate cancer is the cancer of abnormal and uncontrolled growth of cells in the prostate gland of a male which is a part of the male reproductive system, basically it is a small gland shaped like a walnut that produces seminal fluid that helps to maintain sperms and facilitates their transportation. It is the second-most common cancer occurring in men, after skin cancer. Prostate cancer diagnostics depend on several factors, such as how fast cancer is growing, whether it has spread to overall health, as well as the potential benefits or side effects of the treatment.

Based on the test type, the preliminary tests segment is going to have lucrative growth during the forecast period as easy availability of preliminary screening has facilitated early diagnosis and treatment, increasing survival rates. PSA tests are much useful to detect unrecognized and small tumors that may or may not develop into an advanced stage of cancer. As preliminary tests facilitate the detection of cancer before major symptoms appear, they are mostly recommended to most men over the age of 50 and those at risk of developing the disease.

By geography, North America is going to have high growth during the forecast period owing to an increase in incidence of prostate cancer, innovative healthcare solutions, advanced healthcare infrastructure, and rise in concerns about prostate issues around the region. According to the American society of clinical oncology, prostate cancer is the second-most prominent cause of death in the U.S among men suffering from various cancer types. Therefore prostate cancer diagnostics has a huge demand in the North America region.

Some of the key players profiled in the Prostate Cancer Diagnostics Market include Myriad Genetics, Inc., Abbott Laboratories, Genomic Health, Siemens Healthcare GmbH, Beckman Coulter, Inc., Biomérieux SA, Diasorin S.P.A., MDx Health, F. Hoffman-La Roche AG, Bayer AG, Johnson & Johnson, Sanofi, Ambry Genetics and OPKO Health, Inc.

Stages Covered:
• Recurrent/Advanced Prostate Cancer
• Castration-Resistant Prostate Cancer
• Localized Prostate Cancer

Products Covered:
• Instruments
• Reagents & Consumables
• Accessories   

Prostate Cancer Types Covered:
• Squamous Cell Cancer
• Small Cell Carcinoma
• Transitional Cell (or Urothelial) Cancer
• Prostatic Adenocarcinoma
• Ductal Adenocarcinoma
• Small Cell Prostate Cancer
• Acinar Adenocarcinoma  

Sample Types Covered:
• Urine
• Blood
• Tissue

Test Types Covered:
• Blood-Based Assay
• Preliminary Tests
• Immunohistochemistry
• Confirmatory Tests

Ages Covered:
• Age <55
• Age 55-75
• Age>75

Peer Groups Covered:
• Adult
• Pediatric
• Geriatrics

End Users Covered:
• Ambulatory Surgical Centers
• Hospitals
• Cancer Research Institutes
• Clinics
• Independent Diagnostic Laboratories

Sales Channels Covered:
• Direct Channel/Direct Tender
• Distribution Channels (Retail Sales)

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan       
o China       
o India       
o Australia 
o New Zealand
o South Korea
o Rest of Asia Pacific   
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2019, 2020, 2021, 2025 and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

 

1 Executive Summary         
          
2 Preface         
 2.1 Abstract        
 2.2 Stake Holders        
 2.3 Research Scope        
 2.4 Research Methodology        
  2.4.1 Data Mining       
  2.4.2 Data Analysis       
  2.4.3 Data Validation       
  2.4.4 Research Approach       
 2.5 Research Sources        
  2.5.1 Primary Research Sources       
  2.5.2 Secondary Research Sources       
  2.5.3 Assumptions       
          
3 Market Trend Analysis         
 3.1 Introduction        
 3.2 Drivers        
 3.3 Restraints        
 3.4 Opportunities        
 3.5 Threats        
 3.6 Product Analysis        
 3.7 End User Analysis        
 3.8 Emerging Markets        
 3.9 Impact of Covid-19        
          
4 Porters Five Force Analysis         
 4.1 Bargaining power of suppliers        
 4.2 Bargaining power of buyers        
 4.3 Threat of substitutes         
 4.4 Threat of new entrants        
 4.5 Competitive rivalry        
          
5 Global Prostate Cancer Diagnostics Market, By Stage         
 5.1 Introduction        
 5.2 Recurrent/Advanced Prostate Cancer        
 5.3 Castration-Resistant Prostate Cancer        
  5.3.1 Metastatic       
  5.3.2 Non-Metastatic       
 5.4 Localized Prostate Cancer        
          
6 Global Prostate Cancer Diagnostics Market, By Product         
 6.1 Introduction        
 6.2 Instruments        
 6.3 Reagents & Consumables        
 6.4 Accessories        
          
7 Global Prostate Cancer Diagnostics Market, By Prostate Cancer Type         
 7.1 Introduction        
 7.2 Squamous Cell Cancer        
 7.3 Small Cell Carcinoma        
 7.4 Transitional Cell (or Urothelial) Cancer        
 7.5 Prostatic Adenocarcinoma        
 7.6 Ductal Adenocarcinoma        
 7.7 Small Cell Prostate Cancer        
 7.8 Acinar Adenocarcinoma        
          
8 Global Prostate Cancer Diagnostics Market, By Sample Type         
 8.1 Introduction        
 8.2 Urine        
 8.3 Blood        
 8.4 Tissue        
          
9 Global Prostate Cancer Diagnostics Market, By Test Type         
 9.1 Introduction        
 9.2 Blood-Based Assay        
 9.3 Preliminary Tests        
  9.3.1 Prostate-Specific Antigen (PSA) Test       
  9.3.2 Digital Rectal Exam (DRE) Test       
 9.4 Immunohistochemistry        
 9.5 Confirmatory Tests        
  9.5.1 Tissue Biopsy       
  9.5.2 Trans-Rectal Ultrasound        
  9.5.3 PCA3 Tests       
  9.5.4 Imaging Tests       
   9.5.4.1 Ultrasound      
   9.5.4.2 Magnetic Resonance Imaging (MRI)      
    9.5.4.2.1 Multiparametric Magnetic Resonance Imaging (MRI)     
    9.5.4.2.2 Magnetic Resonance Imaging (MRI) Fusion-Guided Prostate Biopsy     
   9.5.4.3 Computerized Tomography (CT) Scan      
   9.5.4.4 Bone Scan      
   9.5.4.5 Positron Emission Tomography-Computerized Tomography (PET-CT) Scan      
  9.5.5 Biomarker       
   9.5.5.1 Tumor Biomarker Tests      
   9.5.5.2 Ribonucleic Acid (RNA) Biomarkers      
   9.5.5.3 Deoxyribonucleic Acid (DNA) Biomarkers      
   9.5.5.4 Protein Biomarkers      
          
10 Global Prostate Cancer Diagnostics Market, By Age         
 10.1 Introduction         
 10.2 Age <55        
 10.3 Age 55-75        
 10.4 Age>75        
          
11 Global Prostate Cancer Diagnostics Market, By Peer Group         
 11.1 Introduction        
 11.2 Adult        
 11.3 Pediatric        
 11.4 Geriatrics         
          
12 Global Prostate Cancer Diagnostics Market, By End User         
 12.1 Introduction        
 12.2 Ambulatory Surgical Centers        
 12.3 Hospitals        
 12.4 Cancer Research Institutes        
 12.5 Clinics        
 12.6 Independent Diagnostic Laboratories        
          
13 Global Prostate Cancer Diagnostics Market, By Sales Channel         
 13.1 Introduction        
 13.2 Direct Channel/Direct Tender        
 13.3 Distribution Channels (Retail Sales)        
           
14 Global Prostate Cancer Diagnostics Market, By Geography         
 14.1 Introduction        
 14.2 North America        
  14.2.1 US       
  14.2.2 Canada       
  14.2.3 Mexico       
 14.3 Europe        
  14.3.1 Germany       
  14.3.2 UK       
  14.3.3 Italy       
  14.3.4 France       
  14.3.5 Spain       
  14.3.6 Rest of Europe       
 14.4 Asia Pacific        
  14.4.1 Japan       
  14.4.2 China       
  14.4.3 India       
  14.4.4 Australia       
  14.4.5 New Zealand       
  14.4.6 South Korea       
  14.4.7 Rest of Asia Pacific       
 14.5 South America        
  14.5.1 Argentina       
  14.5.2 Brazil       
  14.5.3 Chile       
  14.5.4 Rest of South America       
 14.6 Middle East & Africa        
  14.6.1 Saudi Arabia       
  14.6.2 UAE       
  14.6.3 Qatar       
  14.6.4 South Africa       
  14.6.5 Rest of Middle East & Africa       
          
15 Key Developments         
 15.1 Agreements, Partnerships, Collaborations and Joint Ventures         
 15.2 Acquisitions & Mergers        
 15.3 New Product Launch        
 15.4 Expansions        
 15.5 Other Key Strategies        
          
16 Company Profiling         
 16.1 Myriad Genetics, Inc.        
 16.2 Abbott Laboratories         
 16.3 Genomic Health        
 16.4 Siemens Healthcare GmbH        
 16.5 Beckman Coulter, Inc.        
 16.6 Biomérieux SA        
 16.7 Diasorin S.P.A.        
 16.8 MDx Health        
 16.9 F. Hoffman-La Roche AG        
 16.10 Bayer AG        
 16.11 Johnson & Johnson        
 16.12 Sanofi        
 16.13 Ambry Genetics        
 16.14 OPKO Health, Inc.        

 

Prostate Cancer Diagnostics - Global Market Outlook (2020-2028)

List of Tables          
1 Global Prostate Cancer Diagnostics Market Outlook, By Region (2019-2028) ($MN)         
2 Global Prostate Cancer Diagnostics Market Outlook, By Stage (2019-2028) ($MN)         
3 Global Prostate Cancer Diagnostics Market Outlook, By Recurrent/Advanced Prostate Cancer (2019-2028) ($MN)         
4 Global Prostate Cancer Diagnostics Market Outlook, By Castration-Resistant Prostate Cancer (2019-2028) ($MN)         
5 Global Prostate Cancer Diagnostics Market Outlook, By Metastatic (2019-2028) ($MN)         
6 Global Prostate Cancer Diagnostics Market Outlook, By Non-Metastatic (2019-2028) ($MN)          
7 Global Prostate Cancer Diagnostics Market Outlook, By Localized Prostate Cancer (2019-2028) ($MN)         
8 Global Prostate Cancer Diagnostics Market Outlook, By Product (2019-2028) ($MN)         
9 Global Prostate Cancer Diagnostics Market Outlook, By Instruments (2019-2028) ($MN)         
10 Global Prostate Cancer Diagnostics Market Outlook, By Reagents & Consumables (2019-2028) ($MN)         
11 Global Prostate Cancer Diagnostics Market Outlook, By Accessories (2019-2028) ($MN)         
12 Global Prostate Cancer Diagnostics Market Outlook, By Prostate Cancer Type (2019-2028) ($MN)         
13 Global Prostate Cancer Diagnostics Market Outlook, By Squamous Cell Cancer (2019-2028) ($MN)         
14 Global Prostate Cancer Diagnostics Market Outlook, By Small Cell Carcinoma (2019-2028) ($MN)         
15 Global Prostate Cancer Diagnostics Market Outlook, By Transitional Cell (or Urothelial) Cancer (2019-2028) ($MN)         
16 Global Prostate Cancer Diagnostics Market Outlook, By Prostatic Adenocarcinoma (2019-2028) ($MN)         
17 Global Prostate Cancer Diagnostics Market Outlook, By Ductal Adenocarcinoma (2019-2028) ($MN)         
18 Global Prostate Cancer Diagnostics Market Outlook, By Small Cell Prostate Cancer (2019-2028) ($MN)          
19 Global Prostate Cancer Diagnostics Market Outlook, By Acinar Adenocarcinoma (2019-2028) ($MN)         
20 Global Prostate Cancer Diagnostics Market Outlook, By Sample Type (2019-2028) ($MN)         
21 Global Prostate Cancer Diagnostics Market Outlook, By Urine (2019-2028) ($MN)         
22 Global Prostate Cancer Diagnostics Market Outlook, By Blood (2019-2028) ($MN)         
23 Global Prostate Cancer Diagnostics Market Outlook, By Tissue (2019-2028) ($MN)         
24 Global Prostate Cancer Diagnostics Market Outlook, By Test Type (2019-2028) ($MN)         
25 Global Prostate Cancer Diagnostics Market Outlook, By Blood-Based Assay (2019-2028) ($MN)         
26 Global Prostate Cancer Diagnostics Market Outlook, By Preliminary Tests (2019-2028) ($MN)         
27 Global Prostate Cancer Diagnostics Market Outlook, By Prostate-Specific Antigen (PSA) Test (2019-2028) ($MN)         
28 Global Prostate Cancer Diagnostics Market Outlook, By Digital Rectal Exam (DRE) Test (2019-2028) ($MN)         
29 Global Prostate Cancer Diagnostics Market Outlook, By Immunohistochemistry (2019-2028) ($MN)         
30 Global Prostate Cancer Diagnostics Market Outlook, By Confirmatory Tests (2019-2028) ($MN)         
31 Global Prostate Cancer Diagnostics Market Outlook, By Tissue Biopsy (2019-2028) ($MN)         
32 Global Prostate Cancer Diagnostics Market Outlook, By Trans-Rectal Ultrasound (2019-2028) ($MN)         
33 Global Prostate Cancer Diagnostics Market Outlook, By PCA3 Tests (2019-2028) ($MN)         
34 Global Prostate Cancer Diagnostics Market Outlook, By Imaging Tests (2019-2028) ($MN)         
35 Global Prostate Cancer Diagnostics Market Outlook, By Biomarker (2019-2028) ($MN)         
36 Global Prostate Cancer Diagnostics Market Outlook, By Age (2019-2028) ($MN)         
37 Global Prostate Cancer Diagnostics Market Outlook, By Age <55 (2019-2028) ($MN)         
38 Global Prostate Cancer Diagnostics Market Outlook, By Age 55-75 (2019-2028) ($MN)         
39 Global Prostate Cancer Diagnostics Market Outlook, By Age>75 (2019-2028) ($MN)         
40 Global Prostate Cancer Diagnostics Market Outlook, By Peer Group (2019-2028) ($MN)         
41 Global Prostate Cancer Diagnostics Market Outlook, By Adult (2019-2028) ($MN)         
42 Global Prostate Cancer Diagnostics Market Outlook, By Pediatric (2019-2028) ($MN)         
43 Global Prostate Cancer Diagnostics Market Outlook, By Geriatrics (2019-2028) ($MN)         
44 Global Prostate Cancer Diagnostics Market Outlook, By End User (2019-2028) ($MN)          
45 Global Prostate Cancer Diagnostics Market Outlook, By Ambulatory Surgical Centers (2019-2028) ($MN)         
46 Global Prostate Cancer Diagnostics Market Outlook, By Hospitals (2019-2028) ($MN)         
47 Global Prostate Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2019-2028) ($MN)         
48 Global Prostate Cancer Diagnostics Market Outlook, By Clinics (2019-2028) ($MN)         
49 Global Prostate Cancer Diagnostics Market Outlook, By Independent Diagnostic Laboratories (2019-2028) ($MN)         
50 Global Prostate Cancer Diagnostics Market Outlook, By Sales Channel (2019-2028) ($MN)         
51 Global Prostate Cancer Diagnostics Market Outlook, By Direct Channel/Direct Tender (2019-2028) ($MN)         
52 Global Prostate Cancer Diagnostics Market Outlook, By Distribution Channels (Retail Sales) (2019-2028) ($MN)         

 

.